Huong Q McLean1, Herve Caspard2, Marie R Griffin3, Katherine A Poehling4, Manjusha Gaglani5, Edward A Belongia6, H Keipp Talbot3, Timothy R Peters4, Kempapura Murthy5, Christopher S Ambrose2. 1. Center for Clinical Epidemiology & Population Health, Marshfield Clinic Research Institute, 1000 North Oak Ave, Marshfield, WI 54449, USA. Electronic address: mclean.huong@marshfieldclinic.org. 2. MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA. 3. Vanderbilt University Medical Center, 1161 21st Avenue S, Nashville, TN 37232, USA. 4. Wake Forest School of Medicine, 1 Medical Center Blvd, Winston-Salem, NC 27157, USA. 5. Baylor Scott & White Health, Texas A&M Health Science Center College of Medicine, 2401 South 31st Street, Temple, TX 76508, USA. 6. Center for Clinical Epidemiology & Population Health, Marshfield Clinic Research Institute, 1000 North Oak Ave, Marshfield, WI 54449, USA.
Abstract
BACKGROUND: A clinical study found that live attenuated influenza vaccine (LAIV) was superior to inactivated influenza vaccine (IIV) against drifted A(H3N2) viruses in children. During the 2014-2015 influenza season, widespread circulation of antigenically and genetically drifted A(H3N2) viruses provided an opportunity to evaluate subtype-specific vaccine effectiveness (VE) of quadrivalent LAIV (LAIV4) and IIV in children. METHODS: Children (2-17years) with febrile acute respiratory illness <5days' duration were enrolled at 4 outpatient sites in the United States during the 2014-2015 influenza season. Nasal swabs were tested for influenza by reverse transcription polymerase chain reaction; vaccination dates were obtained from medical records or immunization registries. VE was estimated using a test-negative design comparing odds of vaccination among influenza cases and test-negative controls with adjustment for potential confounders. RESULTS: Among 1696 children enrolled, 1511 (89%) were included in the analysis. Influenza was detected in 427 (28%) children; 317 had influenza A(H3N2) and 110 had influenza B. Most influenza isolates were characterized as a drifted strain of influenza A(H3N2) or a drifted strain of B/Yamagata. For LAIV4, adjusted VE was 50% (95% confidence interval [CI], 27-66%) against any influenza, 30% (95% CI, -6% to 54%) against influenza A(H3N2), and 87% (95% CI, 63-96%) against type B. For IIV, adjusted VE was 39% (95% CI, 18-54%) against any influenza, 40% (95% CI, 16-58%) against A(H3N2), and 29% (95% CI, -15% to 56%) against type B. Odds of influenza for LAIV4 versus IIV recipients were similar against influenza A(H3N2) (odds ratio [OR], 1.17; 95% CI, 0.73-1.86) and lower against influenza B (OR, 0.18; 95% CI, 0.06-0.55). CONCLUSIONS: LAIV4 and IIV provided similar protection against a new antigenic variant A(H3N2). LAIV4 provided significantly greater protection than IIV against a drifted influenza B strain. ClinicalTrials.gov identifier: NCT01997450.
BACKGROUND: A clinical study found that live attenuated influenza vaccine (LAIV) was superior to inactivated influenza vaccine (IIV) against drifted A(H3N2) viruses in children. During the 2014-2015 influenza season, widespread circulation of antigenically and genetically drifted A(H3N2) viruses provided an opportunity to evaluate subtype-specific vaccine effectiveness (VE) of quadrivalent LAIV (LAIV4) and IIV in children. METHODS:Children (2-17years) with febrile acute respiratory illness <5days' duration were enrolled at 4 outpatient sites in the United States during the 2014-2015 influenza season. Nasal swabs were tested for influenza by reverse transcription polymerase chain reaction; vaccination dates were obtained from medical records or immunization registries. VE was estimated using a test-negative design comparing odds of vaccination among influenza cases and test-negative controls with adjustment for potential confounders. RESULTS: Among 1696 children enrolled, 1511 (89%) were included in the analysis. Influenza was detected in 427 (28%) children; 317 had influenza A(H3N2) and 110 had influenza B. Most influenza isolates were characterized as a drifted strain of influenza A(H3N2) or a drifted strain of B/Yamagata. For LAIV4, adjusted VE was 50% (95% confidence interval [CI], 27-66%) against any influenza, 30% (95% CI, -6% to 54%) against influenza A(H3N2), and 87% (95% CI, 63-96%) against type B. For IIV, adjusted VE was 39% (95% CI, 18-54%) against any influenza, 40% (95% CI, 16-58%) against A(H3N2), and 29% (95% CI, -15% to 56%) against type B. Odds of influenza for LAIV4 versus IIV recipients were similar against influenza A(H3N2) (odds ratio [OR], 1.17; 95% CI, 0.73-1.86) and lower against influenza B (OR, 0.18; 95% CI, 0.06-0.55). CONCLUSIONS: LAIV4 and IIV provided similar protection against a new antigenic variant A(H3N2). LAIV4 provided significantly greater protection than IIV against a drifted influenza B strain. ClinicalTrials.gov identifier: NCT01997450.
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Jessie R Chung; Brendan Flannery; Christopher S Ambrose; Rodolfo E Bégué; Herve Caspard; Laurie DeMarcus; Ashley L Fowlkes; Geeta Kersellius; Andrea Steffens; Alicia M Fry Journal: Pediatrics Date: 2019-01-07 Impact factor: 7.124
Authors: Sarah A Buchan; Stephanie Booth; Allison N Scott; Kimberley A Simmonds; Lawrence W Svenson; Steven J Drews; Margaret L Russell; Natasha S Crowcroft; Mark Loeb; Bryna F Warshawsky; Jeffrey C Kwong Journal: JAMA Pediatr Date: 2018-09-04 Impact factor: 16.193
Authors: Fadi Shehadeh; Ioannis M Zacharioudakis; Markos Kalligeros; Evangelia K Mylona; Tanka Karki; Robertus van Aalst; Ayman Chit; Eleftherios Mylonakis Journal: Open Forum Infect Dis Date: 2020-06-19 Impact factor: 3.835
Authors: Huong Q McLean; Herve Caspard; Marie R Griffin; Manjusha Gaglani; Timothy R Peters; Katherine A Poehling; Christopher S Ambrose; Edward A Belongia Journal: JAMA Netw Open Date: 2018-10-05
Authors: Katherine A Poehling; Herve Caspard; Timothy R Peters; Edward A Belongia; Blaise Congeni; Manjusha Gaglani; Marie R Griffin; Stephanie A Irving; Poornima K Kavathekar; Huong Q McLean; Allison L Naleway; Kathleen Ryan; H Keipp Talbot; Christopher S Ambrose Journal: Clin Infect Dis Date: 2018-02-10 Impact factor: 9.079
Authors: Sophie A Valkenburg; Nancy H L Leung; Maireid B Bull; Li-Meng Yan; Athena P Y Li; Leo L M Poon; Benjamin J Cowling Journal: Front Immunol Date: 2018-07-02 Impact factor: 7.561